Does the route of administration of misoprostol make a difference? The uterotonic effect and side effects of misoprostol given by different routes after vaginal delivery

被引:34
作者
Chong, YS
Chua, S
Shen, L
Arulkumaran, S
机构
[1] St George Hosp, Sch Med, Dept Obstet & Gynaecol, London SW17 0RE, England
[2] Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore 117548, Singapore
[3] Clin Trials & Epidemiol Res Unit, Singapore, Singapore
基金
英国医学研究理事会;
关键词
misoprostol; route of administration; uterotonic; side effects; postpartum haemorrhage;
D O I
10.1016/j.ejogrb.2003.09.011
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the postpartum uterotonic effect and side effects of misoprostol administered by different routes. Study design: Fifty women were given misoprostol 400 mug either by the oral solution, oral tablet, rectal or vaginal route, or intramuscular syntometrine 1 ml after spontaneous vaginal delivery. Pre- and post-treatment uterine activity were measured with intrauterine pressure catheters. Results: Uterine activity produced by oral solution misoprostol 400 mug was significantly higher than that of oral tablet, rectal and vaginal misoprostol (P = 0.045, 0.004, 0.002, respectively). Onset of action after oral solution misoprostol was faster than by the oral tablet (P = 0.01), rectal (P < 0.001) and vaginal (P < 0.001) routes. Shivering and pyrexia were most common with oral solution misoprostol. Maximum body temperature recorded was significantly higher with oral solution misoprostol than with oral tablet, rectal and vaginal misoprostol (P = 0.005, 0.009, 0.001, respectively). Conclusion: Different routes of administering misoprostol greatly influence the effects achieved. Oral solution misoprostol produces the fastest and strongest uterotonic effect, with the most side effects. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:191 / 198
页数:8
相关论文
共 40 条
[1]   The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration [J].
Abdel-Aleem, H ;
Villar, J ;
Gülmezoglu, AM ;
Mostafa, SA ;
Youssef, AA ;
Shokry, M ;
Watzer, B .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2003, 108 (01) :25-28
[2]   A randomized, controlled trial comparing effect of oral misoprostol and intravenous syntocinon on intra-operative blood loss during cesarean section [J].
Acharya, G ;
Al-Sammarai, MT ;
Patel, N ;
Al-Habib, A ;
Kiserud, T .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2001, 80 (03) :245-250
[3]   Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double-blind randomised trial [J].
Amant, F ;
Spitz, B ;
Timmerman, D ;
Corremans, A ;
Van Assche, FA .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (10) :1066-1070
[4]   Rectal misoprostol in the prevention of postpartum hemorrhage: A placebo-controlled trial [J].
Bamigboye, AA ;
Hofmeyr, GJ ;
Merrell, DA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (04) :1043-1046
[5]   Randomized comparison of rectal misoprostol with Syntometrine for management of third stage of labor [J].
Bamigboye, AA ;
Merrell, DA ;
Hofmeyr, GJ ;
Mitchell, R .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1998, 77 (02) :178-181
[6]   Misoprostol for prevention of postpartum hemorrhage [J].
Bugalho, A ;
Daniel, A ;
Faúndes, A ;
Cunha, M .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2001, 73 (01) :1-6
[7]   Oral misoprostol for the third stage of labor:: A randomized controlled trial [J].
Çaliskan, E ;
Dilbaz, B ;
Meydanli, MM ;
Öztürk, N ;
Narin, MA ;
Haberal, A .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (05) :921-928
[8]   Is rectal misoprostol really effective in the treatment of third stage of labor?: A randomized controlled trial [J].
Çaliskan, E ;
Meydanli, MM ;
Dilbaz, B ;
Aykan, B ;
Sönmezer, M ;
Haberal, A .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (04) :1038-1045
[9]  
Chong Yap Seng, 1997, Obstetrics and Gynecology, V90, P703, DOI 10.1016/S0029-7844(97)00275-5
[10]  
Chong YS, 2002, HUM REPROD, V17, P2777, DOI 10.1093/humrep/17.10.2777